TGTX - TG Therapeutics, Inc.
NEXT EARNINGS:
Mar 2, 2026
(in 5 days)
EPS Est: $0.38
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$49.50
DETAILS
HIGH:
$60.00
LOW:
$39.00
MEDIAN:
$49.50
CONSENSUS:
$49.50
UPSIDE:
62.24%
Market Cap:
4.84B
Volume:
1,259,759
Avg Volume:
1,800,383
52 Week Range:
25.28-46.48
Sector:
Healthcare
Industry:
Biotechnology
Beta:
1.87
Last Dividend:
$N/A
Exchange:
NASDAQ
Country:
US
Employees:
352
IPO Date:
2010-05-03
EPS (TTM):
0.16
P/E Ratio:
187.06
Revenue (TTM):
329.00M
Total Assets:
577.69M
Total Debt:
253.72M
Cash & Equiv:
179.89M
Rev Growth (5Y):
364.3%
EPS Growth (5Y):
-27.9%
FCF Growth (5Y):
N/A
ROCE:
10.2%
Debt/Equity:
1.14
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2025-11-03 | $2.43 | $0.24 | +912.5% | $161.7M | $193.8M | -16.6% |
| 2025-08-04 | $0.17 | $0.32 | -46.9% | $141.1M | $146.3M | -3.5% |
| 2025-05-05 | $0.03 | $0.18 | -83.3% | $120.9M | $134.2M | -9.9% |
| 2025-03-03 | $0.15 | $0.08 | +87.5% | $108.2M | $108.8M | -0.6% |
| 2024-11-04 | $0.02 | $0.03 | -33.3% | $83.9M | $98.8M | -15.1% |
| 2024-08-06 | $0.04 | $-0.05 | +180.0% | $73.5M | $65.9M | +11.5% |
| 2024-05-01 | $-0.07 | $-0.04 | -96.0% | $63.5M | $54.6M | +16.2% |
| 2024-02-28 | $-0.09 | $-0.12 | +25.0% | $44.0M | $40.1M | +9.8% |
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 329.00M | 233.66M | 2.79M | 6.69M | 152,000 | 152,000 | 152,000 | 152,381 | 152,381 | 152,381 | 152,381 | 152,381 |
| Net Income | 23.38M | 12.67M | (223.81M) | (348.10M) | (279.38M) | (172.87M) | (173.48M) | (118.48M) | (78.25M) | (62.95M) | (55.78M) | (20.48M) |
| EPS | 0.16 | 0.09 | -1.46 | -2.63 | -2.42 | -1.96 | -2.30 | -1.91 | -1.60 | -1.38 | -1.64 | -0.81 |
| Total Assets | 577.69M | 329.59M | 193.57M | 379.63M | 625.64M | 163.01M | 83.62M | 97.38M | 54.78M | 113.47M | 86.75M | 48.11M |
| Total Debt | 253.72M | 110.80M | 83.06M | 79.05M | 41.98M | 40.80M | 67,000 | 127,614 | 68,875 | 211,549 | 275,190 | 742,307 |
| Cash & Equivalents | 179.89M | 92.93M | 102.30M | 298.89M | 553.44M | 112.64M | 41.96M | 56.72M | 25.03M | 55.06M | 55.71M | 40.49M |
| Operating Cash Flow | (40.52M) | (31.41M) | (176.17M) | (295.63M) | (214.51M) | (132.81M) | (128.93M) | (93.76M) | (61.59M) | (44.69M) | (35.06M) | (10.82M) |
| Free Cash Flow | (40.56M) | (31.41M) | (176.18M) | (296.04M) | (214.86M) | (132.94M) | (129.01M) | (93.77M) | (61.94M) | (44.73M) | (35.08M) | (10.83M) |
| FCF per Share | -0.28 | -0.22 | -1.30 | -2.24 | -1.86 | -1.50 | -1.71 | -1.51 | -1.26 | -0.98 | -1.03 | -0.43 |
| Book Value | 222.36M | 160.50M | 58.59M | 237.15M | 519.35M | 38.62M | 24.04M | 66.99M | 35.87M | 101.57M | 80.10M | 40.05M |
| Cash & ST Investments | 311.00M | 217.51M | 161.68M | 314.76M | 605.43M | 140.44M | 68.81M | 84.83M | 44.97M | 102.42M | 78.86M | 45.43M |
| ROC Equity | 0.11 | 0.08 | -3.82 | -1.47 | -0.54 | -4.48 | -7.22 | -1.77 | -2.18 | -0.62 | -0.70 | -0.51 |